Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More

Philipp Schreiner\textsuperscript{a}  Markus F. Neurath\textsuperscript{b}  Siew C. Ng\textsuperscript{c}  Emad M. El-Omar\textsuperscript{d}  
Ala I. Sharara\textsuperscript{e}  Taku Kobayashi\textsuperscript{f}  Tadakazu Hisamatsu\textsuperscript{g}  Toshifumi Hibi\textsuperscript{f}  Gerhard Rogler\textsuperscript{a}

\textsuperscript{a}Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland; \textsuperscript{b}Medizinische Klinik 1, Universitätsklinikum Erlangen-Nürnberg, Erlangen, Germany; \textsuperscript{c}Department of Medicine and Therapeutics, Institute of Digestive Disease, LKS Institute of Health Science, State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China; \textsuperscript{d}St. George and Sutherland Clinical School, University of New South Wales, Sydney, NSW, Australia; \textsuperscript{e}Division of Gastroenterology, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon; \textsuperscript{f}Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan; \textsuperscript{g}3rd Department of Internal Medicine, Kyorin University, Tokyo, Japan

Abstract

Background: Although TNF inhibitors revolutionized the therapy of inflammatory bowel disease (IBD), we have been reaching a point where other therapies with different mechanisms of action are necessary. A rising number of elderly IBD patients with contraindications to established therapies and a growing group of patients losing response to anti-TNF therapy compel us to find safer, better-tolerated, and, ideally, personalized treatment options. However, in order to choose the right drug to fit a patient, it is indispensable to understand the pathomechanism involved in IBD. 

Summary: The aim of this review is to explain the inflammatory signaling pathways in IBD and how to inhibit them with current and future therapeutic approaches. Next to biologic agents targeting inflammatory cytokines (anti-TNF agents, anti-IL-12/23 agents, and specific inhibitors of IL-23), biologics blocking leukocyte trafficking to the gut (anti-integrin antibodies) are available nowadays. More recently, small molecules inhibiting the JAK-STAT pathway (JAK inhibitors) or preventing lymphocyte trafficking (sphingosine-1-phosphate modulators) have been approved or are under investigation. Furthermore, modifying the microbiota has potential therapeutic effects on IBD, and autologous hematopoietic or mesenchymal stem cell transplantation may be considered for a highly selected group of IBD patients. Key Message: Physicians should understand the different mechanisms of action of the potential therapies for IBD to select the right drug for the right patient.

Introduction

In recent years, our understanding of the pathogenesis of inflammatory bowel disease (IBD) with its two main entities, ulcerative colitis (UC) and Crohn’s disease (CD), has increased considerably. IBD is a chronic inflammatory disease believed to be triggered by specific or multiple environmental factors in genetically...
susceptible individuals. An impaired mucosal barrier together with disturbed luminal microbiota finally lead to a consecutive dysregulation of the intestinal immune system [1].

Although current strategies connect this knowledge of disease pathogenesis with new mechanisms of action for potential therapies, there is still no cure in sight. Instead, a global increase in the incidence and prevalence of IBD can be observed [2, 3], which is mainly driven by higher incidence rates in Asian and South American countries and due to a demographic shift with a growing, older IBD population [4], inevitably leading to a higher prevalence. Despite the fact that the course of elderly-onset IBD is often mild and associated with a lower use of immunosuppressants [5, 6], these IBD patients represent a difficult-to-treat patient group with many aspects to be considered [7].

Interestingly, the incidence of IBD in Western countries – after a tremendous rise in the past 50 years [8] – finally seems to increase more slowly or reach a plateau. Nevertheless, IBD has still the highest incidence and prevalence (exceeding 0.3%) in North America, Oceania, and Europe [3, 9]. As mentioned above, we experience an increase in the incidence of IBD in Asian countries [3, 8, 10]. Considering China with a population of nearly 1.4 billion and India with 1.3 billion people, the increase in IBD in these countries [11–14] creates huge economic challenges. However, it also provides the opportunity to better understand the epidemiological aspects of IBD and to investigate the factors that lead to IBD, which finally may help us to develop new therapies.

This review highlights novel therapies for CD and UC based on novel insights into the highly complex pathogenesis of IBD, including anti-cell adhesion molecules; therapies capable of blocking proinflammatory cytokines and stopping downstream signaling; molecules preventing lymphocyte trafficking; and strategies influencing the microbiota and stem cell therapy. The available agents and therapies under investigation are summarized in Table 1.

Cytokines

**TNF Inhibitors**

The proinflammatory cytokine TNF-α plays a major role in the immunopathogenesis of IBD [15]. In IBD, the production of soluble and membrane-bound TNF is significantly increased through CD14+ macrophages, fibroblasts, and T cells [16].

At the turn of the millennium, the advent of infliximab, a chimeric antibody against TNF comprising 25% murine sequence and 75% human sequence, marked an important milestone in the therapy for refractory IBD. In 1997, Targan et al. [17] published the first controlled study demonstrating the efficacy of infliximab in CD patients. More placebo-controlled trials of CD [18, 19] and, later on, of UC [20] followed, so that nowadays infliximab is a mainstay of IBD therapy particularly for patients who do not respond to conventional therapies [21]. In the past decade, three other subcutaneous TNF inhibitors have become available. Adalimumab, a fully human monoclonal antibody, has been shown to induce and maintain remission in moderate-to-severe CD [22–24] and UC [25–27]. For certolizumab, a humanized Fab (antigen-binding fragment) lacking the fragment crystallizable (Fc) region, successful induction and remission could be demonstrated in CD [28, 29] – and, likewise, for golimumab, a fully human antibody, in UC [30, 31].

No randomized controlled trials (RCTs) of certolizumab in UC or golimumab in CD have been published. However, in the last years some retrospective studies have demonstrated the efficacy and safety of golimumab in CD [32, 33]. Furthermore, the first results of an open-label maintenance study with certolizumab pegol showed its effectiveness in UC [34], and a phase II study is still ongoing [35]. Recently, meta-analyses have confirmed the efficacy of TNF inhibitors in CD and UC [36–38].

Interestingly, etanercept – a soluble recombinant TNF receptor also binding to circulating TNF, thereby neutralizing it – failed to show efficacy in CD, leading to the concept that the therapeutic effect of anti-TNFs in IBD must be due to mechanisms other than only TNF neutralization [39]. One explanation for this finding is that both membrane-bound and soluble TNF need to be neutralized to induce T-cell apoptosis in vivo. Blocking soluble TNF alone, as postulated for etanercept, has no therapeutic effect on IBD [16, 40]. However, it has never been investigated in detail whether a soluble TNF receptor fails to block membrane-bound TNF.

In summary, it has to be admitted that the exact mechanism of action of anti-TNF agents in IBD is not fully understood. It is generally assumed that inhibition of the membrane-bound TNF/TNFR2 pathway is crucially involved in inducing T-cell apoptosis [41], consequently inhibiting downstream proinflammatory pathways.

Although TNF inhibitors revolutionized the treatment of IBD, it must be remembered that more than a third of patients are primary nonresponders [42] and that the annual risk for loss of response (LOR) is about 13% per...
patient-year of treatment with infliximab and around 20% per patient-year [43] with adalimumab. Eventually, around 40% of initial responders will definitively lose response to infliximab [44]. Even though we can counteract immunogenicity as the key mechanism in primary non-response and LOR by combining infliximab with azathioprine [45, 46], by increasing the dose [47], or by shortening the treatment interval [48], many other unsolved problems remain with TNF inhibitors and their short- and long-term treatment efficacy.

One major concern is the economic burden of biologics. Nowadays, two biosimilars of infliximab, CT-P13 (Infectra; Remsima) and SB2 (Flixabi), are on the market with an approximately 30% lower price than that of the reference product [49]. Since biosimilars are manufactured with a different cell line and the manufacturing technique may differ slightly from its original product, they are highly similar copy versions of the originators, but not identical. This slight discrepancy between biosimilars has raised substantial caution about their use [50]. In recent years, more real-life data have become available demonstrating no significant differences in efficacy or safety between biosimilars and their reference product [51–53]. A large French equivalence cohort study investigating more than 5,000 CD patients confirmed the equivalent effectiveness of CT-P13 and infliximab [54].

Table 1. Available agents and therapies for Crohn’s disease and ulcerative colitis under investigation

| Cytokines | Crohn’s disease | Ulcerative colitis | Remarks |
|-----------|----------------|--------------------|---------|
| TNF inhibitors | | | |
| Infliximab | ✓ | ✓ | |
| Adalimumab | ✓ | ✓ | |
| Certolizumab | ✓ | Phase II trial ongoing | |
| Golimumab | ✓ | Phase II trial ongoing | |
| Etanercept | (✓)* | ✓ | * Retrospective studies in Crohn’s disease |
| IL-23/Th17 | | | |
| Ustekinumab | ✓ | Phase III trial ongoing | |
| Risankizumab | ✓ (phase II) | Phase III trial ongoing | |
| Brazikumab | ✓ (phase II) | Phase II trial ongoing | |
| Mirikizumab | Phase II trial ongoing | ✓ (phase II) | |
| IL-17 | | | |
| Secukinumab | Not effective* | No data | * Even higher Crohn’s disease activity with secukinumab |
| IL-6 | | | |
| Tocilizumab | Not effective* | No data | * Only clinical response |
| PF-04236921 | ✓ (phase II)* | Phase III trial ongoing | * Higher rates of perforation |
| PDE4 inhibitor | | | |
| Apremilast | No data | ✓ (phase II) | |
| JAK inhibitors | | | |
| Tofacitinib | Not effective (phase II) | ✓ | * Mucosal healing comparable to that with placebo |
| Filgotinib | ✓* | Phase III trial ongoing | |
| Upadacitinib | ✓ (phase II) | Phase III trial ongoing | |
| Peficitinib | No data | Not effective* | * Trends for increased remission and response |
| Anti-trafficking therapies | | | |
| Anti-cell adhesion | | | |
| Natalizumab | ✓ | No data (only one open-label trial) | Increased risk of PML |
| Vedolizumab | ✓ | ✓ | |
| Etrolizumab | Phase III trial ongoing | ✓ (phase II) | |
| Abrilumab | Not effective (phase II) | ✓ (phase II) | |
| Anti-MAdCAM-1 | | | |
| PF-00547659 | Not effective* | ✓ (phase II) | * High placebo clinical response and remission rates |
| Small-molecule integrin antagonists | | | |
| AJM300 | Not effective | ✓ | |
| PTG-100 | No data | Phase II trial stopped | Study discontinued due to futility-based outcome |
| S1P receptor modulators | | | |
| Ozanimod | Phase III trial ongoing | ✓ (phase II) | |
| Etrasimod | No data | ✓ (phase II) | |
Furthermore, switching from the infliximab originator to CT-P13 can be conducted safely and feasibly without having to expect more serious adverse events [55–58]. Based on the growing number of data on IBD patients treated with biosimilars, the European Crohn’s Colitis Organisation (ECCO) states that switching from the originator to a biosimilar in IBD patients is acceptable [59]. Currently, many more biosimilars of adalimumab and infliximab are in the pipeline [49].

Besides the abovementioned immunogenicity and the substantial costs, the two most feared concerns regarding anti-TNF therapy are deleterious adverse events, particularly serious or opportunistic infections and malignancy. Especially in combination therapy with azathioprine, but also less pronounced with anti-TNF monotherapy, there exists a nonnegligible risk of lymphoma [60]. Furthermore, the risk of serious infections in anti-TNF-treated patients is significantly increased [61, 62] and develops at around an annual rate of 2% [63]. The risk is even higher with combination therapy [62] and in elderly patients above 65 years of age, where the absolute risk can be 2- to 3-fold greater than in younger patients [62]. Compared to patients without immunosuppression, the risk of opportunistic infection is approximately 2- to 3-fold increased [64, 65], which is comparable to the infection risk with corticosteroids [64].

Newer biologics and small molecules with a better safety profile and the possibility of being used as “rescue” treatments have been developed and are described below.

**IL-23/Th17 Pathway**

Recent concepts of the pathophysiology of IBD suggest a disturbed adaptive immune response, with an excessive Th1 immune reaction especially in CD; it is discussed that this is induced by IL-12, leading to the production of large amounts of interferon-γ (IFN-γ), TNF, and IL-6. In contrast, UC is considered a Th2 immune response, with an increased release of IL-5, IL-6, IL-13, and TNF [66]. More recent data have implicated the innate immune system and the IL-23/Th17 axis as being pivotal to the pathogenesis of IBD. A genetic variant of IL23R, the gene encoding a subunit of a receptor for IL-23, which is a cytokine involved in the differentiation of Th17 cells, has been found to be significantly associated with CD [67]. Activation of IL-23, with its subunits p19 and p40, triggers the differentiation of naïve T cells into Th17 cells, which then produce IL-17A, IL-17F, and IL-21, thereby suppressing regulatory T-cell activity [16]. Th17 cells are considered to build a bridge between the adaptive and the innate immune system [68]. Interestingly, apoptosis-resistant IL-23R-positive T cells expand in anti-TNF-refractory patients, leading to the hypothesis that IL-23 antagonists are suitable agents for anti-TNF-refractory patients [69].

Next to activation of the IL-23/Th17 pathway through antigen-presenting cells, the induction of other members of the IL-12 family (consisting of IL-12, IL-23, IL-27, and IL-35) [16] is upregulated in intestinal inflammation. Of special interest in CD is IL-12, composed of the subunits p35 and p40, which induces the differentiation of naïve T cells into Th1 cells with concomitant production of TNF and IFN-γ [70]. Several agents interfering with the pathways of IL-23/IL-12 have been developed or are under investigation and show promising results, especially in CD patients. In contrast, attempts to inhibit IL-17A or IL-17R in IBD have remained unsuccessful.

Ustekinumab is a fully human IgG1 monoclonal antibody that blocks the p40 subunit of IL-12/IL-23. Although a phase IIa induction trial failed to show any superiority of ustekinumab over placebo regarding clinical response at week 8 in moderate-to-severe CD (49 vs. 40%, p = 0.340), interestingly, in patients who were infliximab experienced, the clinical response was stronger with ustekinumab than with placebo (59 vs. 26%, p = 0.022) [71]. The phase III trial (CERTIFI) demonstrated a stronger clinical response in patients receiving 6 mg of ustekinumab per kilogram body weight (39.7 vs. 23.5%, p = 0.005), but the rate of clinical remission did not differ significantly between the groups. Furthermore, patients who responded to ustekinumab in the induction phase had increased rates of response and remission in maintenance therapy with ustekinumab [72]. The UNITI-1 (TNF antagonist failures) and UNITI-2 (conventional therapy failures) trials confirmed the previously published data with even better results particularly for anti-TNF-experienced patients, showing significant efficacy in inducing a clinical response in moderately to severely active CD and maintaining remission in patients responding to induction therapy [73]. More recent data support the high maintenance rates in IM-UNITI (a phase III ustekinumab maintenance study in patients with CD) through week 92 without occurrence of serious adverse events, confirming its long-term efficacy and safety in CD patients [74]. A recently performed substudy demonstrated a reduced simplified endoscopic activity score for CD at week 8 and week 44 [75]. Maintenance trough levels of ustekinumab above 4.5 μg/mL after at least 26 weeks of therapy were associated with a stronger endoscopic response (75.9 vs. 40.7%, p = 0.008) and a lower mean level of C-reactive protein (12.6 vs. 23.9 mg/L,
Furthermore, ustekinumab induced a favorable clinical response after 6 months of therapy in a refractory population with chronic pouchitis and CD of the pouch [77]. The first results of a phase III trial showed promising results in moderate-to-severe active UC patients treated with ustekinumab [78].

With risankizumab, a humanized monoclonal IgG1 antibody that selectively targets the p19 subunit of IL-23, another agent influencing the IL-23 signaling pathway is under investigation. The promising results of a randomized, double-blind, phase II study in patients with moderate-to-severe CD, in whom over 70% of the patients had previously received at least two anti-TNF agents, showed higher clinical and endoscopic remission rates (31 vs. 15%, p = 0.049, and 17 vs. 3%, p = 0.002, respectively) [79]. The extension study confirmed the efficacy of risankizumab in maintaining clinical remission at week 52 and suggests that extended treatment of patients not in deep remission at week 12 increases clinical response and remission rates at week 26 [80]. The most serious adverse events were of gastrointestinal origin [79, 80].

Similar to risankizumab, brazikumab (MEDI2070, formerly AMG 139) is a monoclonal antibody binding selectively to the p19 subunit of IL-23. The first results of a phase IIa study in moderate-to-severe CD patients who failed treatment with an anti-TNF antibody are promising. In the brazikumab group, significantly higher rates of clinical improvement at week 8 could be demonstrated than in the placebo group (49.2 vs. 26.7%, p = 0.010) [81].

Although the IL-23 axis is thought to be mainly involved in CD, the first results of a completed induction phase of a phase II study with mirikizumab (LY3074828), a p19-directed anti-IL-23 antibody, showed positive results regarding clinical response and remission at week 12 in moderate-to-severe UC patients [82]. These results have to be confirmed in further studies, but they are encouraging with regard to enlarging the armamentarium for the treatment of UC.

**Anti-IL-17**

Despite overexpression of IL-17 in CD tissue [83], a known risk polymorphism of IL23R associated with CD [67], and the effect of anti-IL-17 agents in other inflammatory diseases [84, 85], a proof-of-concept study failed to show any efficacy of secukinumab, an IL-17 inhibitor, in CD patients. Patients treated with secukinumab suffered from higher CD activity than patients treated with placebo [86]. Furthermore, some recently published case reports presented the emergence of IBD in patients treated with secukinumab [87]. This deleterious effect with an anti-IL-17 antibody on CD has shown the limitations of our understanding of the complex system of cytokines involved in the pathogenesis of IBD. Nowadays, it is assumed that besides a possible proinflammatory effect, IL-17 acts as an important cytokine for homeostasis in the gut, plays a role in wound repair [88], and maintains intestinal barrier integrity [89]. Blockade of IL-17 can subsequently result in an altered integrity of the gut barrier, which has a more substantial impact on causing colitis than the proinflammatory effect of IL-17 [90].

**Anti-IL-6**

Due to the fact that IL-6 possesses multiple proinflammatory effects and its production is upregulated in patients with CD [16], it is another potential target for the treatment of IBD. Interestingly, the IL-6 pathway could be a loophole in patients refractory to anti-TNF and anti-integrin therapy. A study investigating biomarkers of vedolizumab (VDZ) resistance demonstrated that patients with IBD failing anti-TNF and VDZ treatment had significantly higher circulating IL-6 levels [91]. Therefore, it is thought that the IL-6 pathway can cause inflammation independently of TNF.

Tocilizumab, a humanized monoclonal antibody against the IL-6 receptor already used in rheumatoid arthritis [92], has been investigated in a randomized pilot trial in active CD, demonstrating a higher clinical response rate than placebo (80 vs. 31%, p = 0.019), but neither endoscopic nor histological healing [93]. Since the performance of this small study, no further trials of tocilizumab in CD were performed.

Another fully human IgG2 monoclonal antibody binding and neutralizing IL-6 is PF-04236921. In a double-blind, parallel-group trial in CD patients who failed anti-TNF therapy (ANDANTE I and II), PF-04236921 appeared to be efficient in inducing a clinical response and remission at week 12 (47.4 vs. 28.6%, p < 0.050, and 27.4 vs. 10.9%, p < 0.050, respectively) [94]. However, it should be noted that gastrointestinal abscesses and perforation were observed with PF-04236921, a known serious adverse event that has also been reported for tocilizumab [95]. Although most of the perforations occurred in patients having diverticulitis and previously taking nonsteroidal anti-inflammatory drugs [96] (therefore being excluded from the ANDANTE trial), the occurrence of perforation was still present [94]. This disastrous event, especially in patients already suffering from a gastrointestinal disease, may compromise a wide spread of IL-6 antagonists and requires special attention in future clinical trials.

From Pathogenesis to Therapy in IBD

Inflamm Intest Dis 2019;4:79–96
DOI: 10.1159/000500721
Another therapeutic target in TNF-refractory patients is oncostatin M (OSM). OSM belongs to the family of IL-6 cytokines and is highly expressed in active CD and UC patients, particularly with deep ulcerations. Furthermore, a mouse model demonstrated high expression of OSM in TNF-resistant inflamed intestinal mucosa [97]. This finding could lead to a possible new biomarker for therapy responsiveness to TNF treatment, or to a new treatment option.

**Anti-IL-9**

A further interesting approach is to block IL-9 as a therapeutic target in IBD. Patients with UC have elevated IL-9-expressing T cells and cells expressing the transcription factor PU.1, a key regulator of Th9-cell differentiation. An animal model demonstrated the same findings and could show that IL-9- and PU.1-deficient mice were spared from developing colitis [98]. Therefore, it is assumed that IL-9 negatively alters intestinal barrier function by influencing tight junction molecules [99]. These findings can be used in the development of a new treatment option for UC.

**Phosphodiesterase 4 Inhibitor**

Phosphodiesterase 4 (PDE4) is a protein highly expressed in immune cells which catalyzes the breakdown of cyclic AMP (cAMP). cAMP is a key player in the intracellular inflammatory cascade [100], and elevated intracellular cAMP levels suppress the production of various proinflammatory mediators [101] and promote the release of anti-inflammatory mediators [102]. By blocking PDE4, cAMP levels rise, which subsequently results in an anti-inflammatory response [100]. Apremilast is an orally administered PDE4 inhibitor showing anti-inflammatory activity in murine models of colitis through reducing TNF-α, IFN-γ, IL-6, IL-13, and IL-9 [103]. A phase II trial with active UC patients treated with apremilast showed an improvement in symptoms, biomarkers, endoscopy results, and mucosal healing compared to placebo at week 12 [104].

**Janus Kinase Inhibitors**

Janus kinases (JAKs) play a central role in innate and adaptive immune response. Since nearly all cytokines use the JAK signal transducer and activator of transcription (STAT) pathway as a common signaling pathway, JAK inhibitors block the activity of multiple cytokines simultaneously. Cytokines not using the JAK-STAT pathway are TNF, IL-1, IL-8, TGF-β, and macrophage colony-stimulating factor [105].

After binding of a cytokine to its cell surface receptor, the intracellular part of JAK gets activated. Subsequently, JAKs phosphorylate the intracellular part of the cytokine receptor, which allows binding of latent cytoplasmic transcription factors known as STATs. These in turn become tyrosine phosphorylated by the JAKs, dimerize, and translocate to the nucleus to regulate gene expression [106]. Four JAKs are found in humans, namely, JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2), as well as seven STATs, that is, STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6 [106].

JAK inhibitors are small molecules which differ from antibodies or other biologicals in many ways. Unlike biologicals, small molecules have a short half-life, allowing interference with the immunosuppressive effect in case of infection, surgery, or pregnancy. Furthermore, they are efficient at lower doses; thus, they do not block the entire signaling pathway [107]. Patients often prefer orally administered medication over an injectable therapy [108]; hence, small molecules could improve patient acceptance and may increase adherence. Lastly, due to their small size, they confer a much lower risk of immunogenicity and allergic reactions [109, 110].

Tofacitinib, a small molecule, inhibits JAK1 and JAK3, as well as, to a lesser extent, JAK2 and TYK2, which is why it is considered as pan-JAK inhibitor. JAK1/JAK3 dimerization controls signaling of the cytokines IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 [107]. By blocking these signaling pathways, B-cell class switching and differentiation of T cells and NK cells may be suppressed [107, 111].

After a positive phase II trial in moderate-to-severe UC patients [112], three phase III trials with tofacitinib (OCTAVE Induction 1 and 2 and OCTAVE Sustain) followed, which confirmed its efficacy in induction and maintenance therapy compared to placebo in patients with moderately to severely active UC [113] (remission at week 8 in OCTAVE Induction 1 and 2: 18.5 vs. 8.2%, p = 0.007, and 16.6 vs. 3.6%, p < 0.001, respectively; remission at week 52 in OCTAVE Sustain: 34.6% (5 mg) and 40.6% (10 mg) vs. 11.1%, p < 0.001). Observed adverse events were herpes zoster infection and increased lipid levels [113]. The reason for the significantly higher incidence of herpes zoster infection is not known [114]. However, JAK inhibitors block the IL-6 signaling pathway, which may explain the frequent increase in lipid levels also observed with tocilizumab [115], a selective IL-6 antagonist.

A safety analysis up to 8.5 years showed no more adverse events over time than what had been observed in
previous studies [116]. It has to be mentioned, though, that the US Food and Drug Administration (FDA) recently published a warning after an ongoing safety trial had found an increased risk of pulmonary embolism and death among patients with rheumatoid arthritis treated with 10 mg tofacitinib twice daily [117]. A systematic review of studies on rheumatoid arthritis patients treated with tofacitinib, however, did not find an increased risk for malignancy [118].

Despite the fact that no head-to-head trials exist, a systematic review suggested that tofacitinib should be ranked highest for induction of remission and mucosal healing as a second-line agent for patients with moderate-to-severe UC previously treated with an anti-TNF agent [119]. Since a recently published study confirmed the rapid onset of action with significant improvement already within 3 days after starting tofacitinib [120], this drug could possibly be utilized for UC patients in need of a fast-acting agent.

In contrast, in moderately to severely diseased CD patients treated with tofacitinib, clinical remission rates were not significantly different from those with placebo in a phase IIb trial [121]. Interestingly, filgotinib, another orally administered JAK inhibitor selectively targeting JAK1, demonstrated a significantly higher rate of clinical remission and response in CD patients than placebo (47 vs. 23%, \( p = 0.0077 \), and 59 vs. 41%, \( p = 0.0453 \), respectively) in a phase II RCT (FITZROY study) [122]. Anti-TNF-naïve patients had higher remission and response rates than anti-TNF-experienced patients. Nevertheless, endoscopic mucosal healing at week 10 was comparable to that in the placebo group. It may be argued that the optimal timing for endoscopic assessment using JAK inhibitors is unknown and the time of endoscopy at week 10 is too early to observe differences in mucosal healing.

Another JAK inhibitor, currently investigated in a phase II study on anti-TNF-experienced CD patients, is upadacitinib (ABT-494). In this trial, upadacitinib, which inhibits JAK1, demonstrated higher rates of clinical response, remission, and endoscopic improvement than placebo [123]. Although the safety profile was comparable to that of placebo, further studies are needed to confirm the safety and efficacy of upadacitinib.

Peficitinib, another oral JAK inhibitor, targets JAK3 6-fold more frequently than JAK1 and JAK2. In a phase Iib trial on patients with moderate-to-severe UC [124], peficitinib failed to show a dose response at week 8 according to the Mayo score, but trends for increased remission and response rates were observed with doses ≥ 75 mg. Since serum and fecal inflammation markers were not different from those with placebo, it is doubtful whether the peficitinib dose was high enough to reach a biological effect.

Further JAK inhibitors under development for IBD are BMS-986165 and TD-1473. BMS-986165 is a specific Tyk2 inhibitor, blocking the IL-12, IL-23, and Th1 pathway [125] and is under investigation in an ongoing phase II study on moderate-to-severe CD subjects [126].

TD-1473 is a novel orally administered pan-JAK inhibitor that selectively inhibits JAK in the gastrointestinal tract [127]. In a phase Ib study on patients with moderately to severely active UC, TD-1473 was well tolerated and showed low plasma exposure confirming gut selectivity and signals for clinical and biomarker activity [128].

Although the development of JAK inhibitors is still in its infancy, our understanding of the JAK-STAT pathway is increasing, which could lead to more specific JAK inhibitors in the future.

**Anti-Trafficking Therapies**

**Anti-Cell Adhesion Molecules**

After activation of the innate and acquired immune systems by luminal contents and intestinal microbes, multiple inflammatory mediators are released that attract further activated immune cells. The perpetuation of the inflammatory response in the mucosa is supported by the migration of activated lymphocytes and monocytes into the inflamed area [1]. Leukocytes roll along the vascular endothelium and transmigrate through the endothelium to the inflamed mucosa [129]. To achieve adhesion of a leukocyte to endothelial cells, interaction between cell-expressed integrins on the surface of leukocytes and tissue-expressed adhesion molecules is important. The \( \alpha_4 \beta_7 \) integrins on the surface of leukocytes and the mucosal addressin cell adhesion molecule (MAdCAM) on the vascular endothelium play a pivotal role in the migration of gut-homing leukocytes. To inhibit local inflammation, this pathway may be blocked at many sites by different drugs, such as VDZ (specific IgG1 antibody blocking \( \alpha_4 \beta_7 \)), natalizumab (targeting the \( \alpha_4 \) subunit of the \( \alpha_4 \beta_7 \) and \( \alpha_4 \beta_1 \) integrins), etrolizumab (blocks the \( \beta_7 \) integrin subunit), and MAdCAM inhibitors [111].

Natalizumab, a monoclonal antibody directed against the \( \alpha_4 \) subunit, inhibits gut and brain lymphocyte migration through blocking \( \alpha_4 \beta_7 \) and \( \alpha_4 \beta_1 \) integrin-mediated interactions [130]. Induction therapy failed to show superiority of natalizumab over placebo in moderate-to-
severe CD (ENACT-1 trial, 56 vs. 49%, \( p = 0.05 \)), but demonstrated efficacy in sustaining remission in patients who had responded to natalizumab (ENACT-2 trial, 61 vs. 28%, \( p < 0.001 \)) [131]. However, a post hoc analysis of the ENACT-1 trial showed efficacy in patients with active disease. The ENCORE trial confirmed the efficacy of natalizumab in inducing remission in patients with moderately to severely active CD and active inflammation [132].

A serious adverse event of therapy with natalizumab is the occurrence of progressive multifocal leukoencephalopathy (PML) due to JC polyomavirus [131, 133, 134]. However, patients unexposed to immunosuppressive therapy and negative for JC virus antibodies had a very low PML incidence rate of <0.11 per 1,000 [134].

A recently published Cochrane review suggests the effectiveness of natalizumab in induction of clinical remission and response in moderate-to-severe CD [135]. However, the increased risk of PML and the availability of alternative agents limit its use as second-line medication for CD patients. Nevertheless, in retrospective case reviews, natalizumab was used in difficult-to-treat CD patients who had previously failed TNF inhibitor treatment, and it showed efficacy and safety in these patients [136, 137]. Therefore, it could still be an option for difficult-to-treat CD patients and used under a surveillance program (TOUCH Prescribing Program) [138]. Another potential indication is CD with concomitant multiple sclerosis in patients who have never been exposed to immunosuppressants [139].

A further anti-integrin antibody is VDZ, a humanized monoclonal antibody that blocks the entire \( \alpha_4 \beta_7 \) heterodimer. Compared to natalizumab, VDZ selectively prevents leukocyte trafficking to the gut without targeting \( \alpha_4 \beta_7 \) integrin, which modulates brain trafficking. The GEMINI 1 and 2 studies demonstrated that VDZ is more effective than placebo as induction and maintenance therapy in moderate-to-severe UC [140] and CD [141]. In TNF-native UC patients, the efficacy is greater than in patients who have previously failed TNF antagonist treatment. However, it is still an alternative for patients who have previously failed TNF antagonist treatment. The elevated risk of PML with natalizumab was not observed under VDZ treatment [144–146], probably because VDZ does not inhibit \( \alpha_4 \beta_7 \). In addition, due to the gut-selective blockade of \( \alpha_4 \beta_7 \), VDZ has an excellent safety profile without any risk of serious or opportunistic infections [147]. Recently published real-world data support the safety and efficacy of VDZ, even in refractory IBD patients [146, 148], and demonstrate a cumulative rate of deep remission in 30% of patients [149–152].

As with all biologicals, VDZ has the potential for immunogenicity [153], albeit at a low level with an incidence rate of LOR to VDZ of 47.9 per 100 person-years of follow-up in CD and of 39.8 per 100 person-years of follow-up in UC [154]. Patients who have experienced a LOR to an anti-TNF therapy before use of VDZ have a 2-fold increased risk of LOR to VDZ [155]. Interestingly, immunogenicity is higher for anti-TNF antibodies than for VDZ [153], but the rate of LOR to VDZ is not lower than that to anti-TNF therapy [154]. Among patients with LOR to VDZ, shortening of the interval and intensification of the dose lead to a clinical response in around 50% of patients [154, 155].

Despite a lack of head-to-head trials comparing anti-TNF and VDZ therapy, its efficacy and safety profile makes VDZ an interesting first-line biologic, especially for elderly UC patients [156], and can be considered as first-line agent for CD patients when safety is more important than a fast response to therapy [157]. Interestingly, a simulation model regarding the positioning of VDZ in IBD therapy predicts the greatest potential benefit in quality-adjusted life-years due to higher remission rates when VDZ is used prior to anti-TNF therapy [158]. The model therefore considers VDZ as the first-line steroid-sparing medication. However, when choosing the most suitable first-line biological, many aspects have to be considered. In patients with extraintestinal manifestation or patients with acute severe colitis requiring a fast effect of therapy, anti-TNF treatment probably still is the better choice [156, 159]. Although exploratory analyses of the data from the GEMINI 2 trial have confirmed the efficacy of VDZ in fistula closure in patients with fistulizing CD [160], robust data regarding this selective group of patients are lacking. A recently finished placebo-controlled study will hopefully clarify this unanswered question [161].

Etrolizumab is a humanized IgG1 antibody selectively targeting the \( \beta_7 \) integrin subunit. Besides inhibition of leukocyte trafficking to the gut by blocking \( \alpha_4 \beta_7 \)/MADCAM-1 interactions, it further blocks \( \alpha_4 \beta_7 \) E-cadherin interactions, which is believed to be an important mecha-
nism in retention of lymphocytes in the intraepithelial compartment. In a double-blind, placebo-controlled, randomized phase II study, etrolizumab achieved clinical remission at 10 weeks in a significantly higher number of patients with moderate-to-severe UC than did placebo (21% [300 mg] vs. 0%, \( p < 0.010 \), and 10% [300 mg plus loading dose] vs. 10%, \( p = 0.048 \)) [162]. The side effect profile is similar to that of VDZ. Currently, phase III clinical trials are ongoing to confirm the efficacy and safety of etrolizumab.

Other than VDZ, abrilumab (AMG 181) is a complete ly human antibody against \( \alpha_4 \beta_7 \) integrin. A recently published phase IIb trial did not meet the primary endpoint (clinical remission at week 8) in patients with moderate-to-severe CD [163]. In the phase IIb UC study, higher rates of remission at week 8, response, and mucosal healing could be demonstrated [164].

Anti-MAdCAM-1 (PF-00547659)

Anti-MAdCAM-1 is a fully humanized IgG2 antibody targeting MAdCAM-1, an intestinal endothelial cell adhesion molecule. It prevents gut homing in lymphocytes carrying the \( \alpha_4 \beta_7 \) integrin on their surface. The phase II TURANDOT trial demonstrated higher remission rates with PF-00547659 among moderately to severely active UC patients having failed at least one conventional therapy [165]. In contrast, anti-MAdCAM antibody did not reach statistically significant results for clinical response in patients with moderate-to-severe CD who had previously failed anti-TNF or immunosuppressive therapy (phase II OPERA trial), though, unexpectedly, high clinical response and remission rates were observed with placebo [166]. The most common adverse events identified were nasopharyngitis, arthralgia, and headache [165].

Small-Molecule Integrin Antagonists

AJM300 is an oral integrin-targeting agent currently in the pipeline for treatment of IBD. AJM300 is a small-molecule inhibitor targeting the \( \alpha_4 \) integrin subunit [167] and was tested in moderately active UC patients in whom higher rates of clinical response at week 8, clinical remission, and even mucosal healing could be demonstrated [168]. Available in abstract form only, a randomized, double-blind trial demonstrated no significant difference in clinical response in active CD patients [169]. Due to the shared mechanism with natalizumab in blocking \( \alpha_4 \) integrin, there is a potential risk of PML. Although the published data show the efficacy of AJM300 in UC and have not yet demonstrated any risk of PML [168], it remains uncertain whether AJM300 will get a foothold in IBD treatment algorithms.

Another oral anti-integrin is PTG-100 (an \( \alpha_4 \beta_7 \) antagonist peptide). However, a phase IIb study (PROPEL) was discontinued following an interim analysis [170].

Sphingosine-1-Phosphate Receptor Modulator

Sphingosine-1-phosphate (S1P) is a signaling molecule that regulates the traffic of lymphocytes out of the lymphoid organs into the bloodstream and to inflamed tissue. Ozanimod belongs to the group of S1P modulators, which are small molecules downregulating S1P receptor subtypes 1 and 5 on lymphocytes and prevent lymphocyte trafficking out of the lymph nodes to the site of inflammation [171, 172]. In a phase II RCT [173] of moderate-to-severe UC, ozanimod applied in two doses (0.5 and 1.0 mg per day) showed significant improvement in clinical response and remission within the group receiving 1 mg ozanimod per day compared to placebo (16 vs. 6%, \( p = 0.048 \)). Although the rate of endoscopic remission was significantly higher in both treatment groups, no significant difference in histologic remission could be observed at week 8. Probably, as with VDZ, the onset of action occurs later because lymphocytes already present in the inflamed tissue do not get blocked through ozanimod. The frequency of severe adverse events was comparable to that with placebo. However, findings observed with fingolimod, a nonselective S1P receptor modulator, demonstrated multiple adverse events such as viral infections [174], bradyarrhythmias [175], macular edema [176], and respiratory events, which may be explained by its specific mode of action as a S1P modulator. Additionally, several cases of PML during treatment with fingolimod occurred [177]. The long-term safety of ozanimod, including the risk of PML, still needs further evaluation.

Etrasimod (APD334) is another selective S1P receptor modulator under investigation for UC treatment. After two randomized double-blind studies on healthy individuals had demonstrated its safety and a rapid decrease in T-helper and -naïve cells [178], phase II (randomized, double-blind, parallel-group) trials in UC patients were recently completed [179, 180]. The first results of the OA-SIS induction study showed, at week 12, a greater change in Mayo score (difference, 0.99 points; 90% CI, 0.30–1.68; \( p = 0.009 \)), a bigger endoscopic improvement (41.8 vs. 17.8%, \( p = 0.003 \)), and more patients in clinical remission (33.0 vs. 8.1%, \( p < 0.001 \)) among patients treated with 2 mg etrasimod compared to a placebo group [181].

From Pathogenesis to Therapy in IBD

DOI: 10.1159/000500721

Inflamm Intest Dis 2019;4:79–96
Intestinal Mucosa and Gut Flora

Besides a dysfunction of the adaptive immune system, the innate immune response is impaired in IBD. The body’s first defense to luminal antigens in the gut consists of epithelial cells, which are protected by an adherent, hydrophobic mucus layer. This mucus layer is mainly composed of phosphatidylcholine, and to a much lower extent of lysophosphatidylcholine, which both show significantly decreased levels in UC patients [182]. This impaired mucus layer can lead to increased permeability of the intestinal barrier and, consecutively, to mucosal barrier dysfunction in IBD patients [183]. After a proof-of-concept study showing the safety of an orally administered phosphatidylcholine (LT-02) and its efficacy in induction of clinical remission in UC patients compared to placebo [184], two further studies followed [185, 186], and a multicenter trial confirmed these results [187]. Despite previous positive results, a phase III trial has recently been stopped due to lack of efficacy [188]. As the patients in this study were taking mesalazine simultaneously with phosphatidylcholine, it was hypothesized that the topical bioavailability of phosphatidylcholine to the colonic mucus was reduced [189]. Nevertheless, this interesting approach could evolve into a new effective treatment for UC patients, with a favorable safety profile.

Modifying the Microbiota

Patients with IBD have an altered microbiome with a reduction of microbial diversity, which is more pronounced in CD than in UC [190]. This low diversity comes with low amounts of short-chain fatty acid-producing bacteria, higher levels of proteobacteria producing the endotoxin lipopolysaccharide, and a higher potential for mucus-degrading processes [191–193]. These changes can disrupt intestinal barrier integrity and subsequently activate innate immune responses. Therefore, interventions aiming at modifying the microbiota of IBD patients are under investigation. In addition to the highly complex attempt to positively change the microbiota in IBD patients through dietary interventions [194, 195], various options to alter the microbiota in IBD patients are under investigation, namely, administration of probiotics and antibiotics as well as fecal microbiota transplantation (FMT).

Only a few studies demonstrated a benefit of probiotics for UC patients. Probiotics seem to be effective in maintaining remission in UC patients with pouchitis treated with VSL#3 [196] and maintaining remission with Escherichia coli Nissle [197]. In active CD, probiotics do not show any efficacy [198]. Interestingly, probiotic bacteria induce human beta defensin 2 [199], which is an endogenous antimicrobial peptide that is part of innate immunity. Defensins are produced out of epithelial surfaces, “professional phagocytes,” and Paneth cells and regulate host immunity in the gastrointestinal tract [200]. Reduced levels of alpha defensins are shown in ileal CD and reduced levels of beta defensins are seen in colonic CD patients [201, 202]. Only recently, a study demonstrated that orally administered human beta defensin 2 increased the microbiota and significantly improved health in a dextran sulfate sodium-induced colitis mouse model [203]. This result supports a therapeutic application of defensins for IBD patients.

Regarding antibiotics, the data are more limited and controversial [204]. Metronidazole plays a role in prophylaxis of postoperative CD [205] or treatment of perianal CD [204] and, like ciprofloxacin, in pouchitis [206].

Another method of altering the gut microbiota of a patient is to infuse a fecal solution from a donor via the upper or lower gastrointestinal tract of the recipient. FMT gained attention due to excellent results in treating recurrent Clostridium difficile infections [207, 208]. Many case reports and observational studies have suggested a favorable outcome when treating refractory UC with FMT [209]. Furthermore, a systematic review and meta-analysis [210], including four RCTs, suggests a significant efficacy of FMT in UC compared to placebo. Since the only RCT with negative results used a nasoduodenal approach and only two treatment sessions [211], a repetitive colorectal approach is more advisable when treating UC with FMT. This could be demonstrated in an RCT on UC in which an intensive-dosage FMT (1 infusion at the first colonoscopy with following enema 5 days a week for 8 weeks) was compared to placebo [212]. Steroid-free clinical remission and response could be seen in 44 and 54%, respectively, of the FMT-treated patients (vs. 20%, p = 0.021, and 23%, p = 0.004, in the placebo group). In addition, the endoscopic response rate was significantly higher in the FMT group (32 vs. 10%, p = 0.016), even if there was no difference in endoscopic remission rate between the two groups (12 vs. 8%, p = 0.48). The currently available data do not show any difference regarding adverse events [210, 212]. It is important to mention that the response to FMT in most cases is only temporary, and that FMT is not a cure for UC [213].

Although FMT shows promising results, further long-term studies are needed to support its safety and efficacy in treating refractory UC patients.
Stem Cell Therapy

As a last salvage therapy, for highly selected refractory CD patients in whom a surgical procedure is not possible, autologous hematopoietic stem cell transplantation (AHSCT) may be considered [214]. The concept is to reset the immune system through a conditioning regimen that stops inflammation, as well as to restore immune tolerance.

The ASTIC trial, a controlled trial of a large cohort of refractory CD patients undergoing AHSCT who had failed at least three immunosuppressive/biological treatments, demonstrated significant improvement with AHSCT in respect to clinical and endoscopic remission 1 year after AHSCT. Serious adverse events, including one death, occurred due to infections associated with pancytopenia induced by the conditioning regimen [215, 216]. During long-term follow-up over a median time of 3.4 years, 44% of these highly refractory CD patients with multiple previous therapies (a median of 6 previous lines of therapy) were still in remission, and 27% of the patients required no medical therapy [217]. The mortality risk (around 1%) and the rates of infective complications (around one-third) seemed to be comparable to those of other indications for HSCT. Since the patients with the greatest complications were current smokers and patients with perianal disease [216, 217], special precautions must be taken with regard to this subgroup. For patients with an identical twin, an interesting approach regarding safety issues is syngeneic HSCT instead of AHSCT. Due to avoidance of mobilization chemotherapy, the risk of neutropenia and infectious complications can be avoided. One case report of a patient with refractory CD treated with syngeneic HSCT demonstrated that 4 years after transplantation, clinical remission without specific therapy for CD could be possible [218].

Another approach in stem cell therapy is the use of mesenchymal stem cells (MSCs) derived from adipose tissue or bone marrow for treating refractory perianal fistulas in patients with CD. It could be shown that adipose-derived MSCs are as efficacious as bone marrow-derived MSCs [219–222], which leads to the conclusion that the origin of the cells is not that important. An encouraging proof-of-concept study in which allogeneic, expanded adipose-derived MSCs (Cx601) were locally injected into the surrounding tissue of complex perianal fistulas present in CD patients [223] supports the hypothesis of anti-inflammatory and immunomodulatory features of adipose-derived MSCs. Hence, a subsequent phase III randomized, double-blind controlled trial was performed [224]. CD patients with complex perianal fistulas treated with Cx601 significantly more often achieved the primary endpoint defined as combined remission (clinical assessment of closure and absence of collections >2 cm confirmed by MRI) at week 24 than those treated with placebo (51 vs. 36%, p < 0.021) [224]. There were no serious adverse events in the Cx601 group. Long-term data over 1 year confirm the safety and efficacy of Cx601 in fistulizing CD [225] with a combined remission rate of 56.3% (vs. 38.6% in controls; p = 0.010). It is important to mention that patients who were on treatment with anti-TNF or another immunosuppressant were to be maintained on stable doses during the study. Whether these patients could stop their immunosuppression after injection of Cx601 was not addressed.

Although there still are some unanswered questions, it can be assumed that MSC therapy is a safe and minimally invasive option for a highly selected group of CD patients with fistulas unresponsive to biologics.

Conclusions

The anti-TNF era brought hope for the therapy of refractory IBD patients; however, after two decades, several problems are still unsolved and new therapies are urgently needed. Our understanding of the involved cytokines and their downstream pathways has helped us to develop new treatment strategies with different target points within the pathogenesis of IBD. Furthermore, our growing understanding of genetic factors and the microbiome yields further targets for the treatment of IBD and can help us in understanding the onset of the disease and, thereby, in developing prevention strategies.

Statement of Ethics

The authors have no ethical conflicts to disclose.

Disclosure Statement

P. Schreiner: travel support from Falk, UCB, and Pfizer and advisory board honorarium from Pfizer.
T. Kobayashi: lecture fees from AbbVie Inc., Kyorin Pharmaceutical, Mitsubishi Tanabe, EA Pharma, Medtronic Co., Ltd., Janssen, Mochida Pharmaceutical, Takeda Pharmaceutical, Gilead Sciences, Nippon Kayaku, JIMRO, ZERIA Pharmaceutical, Astellas, Asahi Kasei Medical, Takeda Pharmaceutical, and Pfizer; consulting/advisory board fees from AbbVie Inc., Al fresa Pharma, Celltrion, Pfizer, Eli Lilly, Ferring Pharmaceuticals, Covidien, Janssen, Mochida Pharmaceutical, Takeda Pharmaceutical, Gilead
12 Zhao J, Ng SC, Lei Y, Yi F, Li J, Yu L, et al. First prospective, population-based inflammatory bowel disease incidence study in mainland of China: the emergence of “western” disease. Inflamm Bowel Dis. 2013 Aug;19(9):1389–45.

13 Kedia S, Ahuja V. Epidemiology of Inflammatory Bowel Disease in India: The Great Shift East. Inflamm Intest Dis. 2017 Nov;22(2):102–15.

14 Ng SC, Kaplan GG, Tang W, Baneree J, Adigopula B, Underwood FE, et al. Population Density and Risk of Inflammatory Bowel Disease: A Prospective Population-Based Study in 13 Countries or Regions in Asia-Pacific. Am J Gastroenterol. 2019 Jan;114(1):107–15.

15 Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med. 2013 Aug;368(8):754–62.

16 Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014 May;14(5):329–42.

17 Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al.; PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007 Jul;357(3):228–38.

18 Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al.; ACCENT I Study Group. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002 May;359(9317):1541–9.

19 Sands BE, Anderson FH, Bernstein CN, Chey WR, Feagan BG, Ford AC, Hanauer SB, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004 Feb;350(9):876–85.

20 Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec;353(23):2462–76.

21 Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn’s disease. Aliment Pharmacol Ther. 2018 Aug;48(4):394–409.

22 Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, Maclntosh D, et al. Human anti-tumor necrosis factor mononuclear antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006 Feb;130(2):323–33.

23 Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn’s disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007 Jun;146(12):829–38.

24 Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007 Jan;131(1):52–65.

25 Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D’Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012 Feb;142(2):257–65.e1–3.

26 Reinisch W, Sandborn WJ, Hommes DW, D’Haens G, Hanauer S, Schreiber S, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gastroenterology. 2011 Jun;140(6):780–7.

27 Watanabe K, Matsuo T, Hisamatsu T, Nakase H, Motoya S, Yoshimura N, et al. Clinical and Pharmacokinetic Factors Associated with Adalimumab-Induced Mucosal Healing in Patients with Crohn’s Disease. Clin Gastroenterol Hepatol. 2018 Apr;16(4):542–9.e1.

28 Sandborn WJ, Feagan BG, Stoïnov S, Honiball PJ, Rutgeerts P, et al.; ACCENT I Study Group. Efficacy and safety of golimumab in Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002 May;359(9317):1541–9.

29 Zhao J, Ng SC, Lei Y, Yi F, Lee S, Li J, Yu L, et al. First prospective, population-based inflammatory bowel disease incidence study in mainland of China: the emergence of “western” disease. Inflamm Bowel Dis. 2013 Aug;19(9):1389–45.

30 Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn’s disease. Aliment Pharmacol Ther. 2018 Aug;48(4):394–409.

31 Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al.; PURSUIT-SC Study Group. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gut. 2014 Jan;63:85–95.

32 Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al.; PURSUIT-SC Study Group. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014 Jan;146(1):96–109.e1.

33 Martineau C, Flourie B, Wils P, Vaysse T, Martineau A, Parrot S, et al.; Goli-Crohn Study Group. Efficacy and safety of golimumab in Crohn’s disease: a French national retrospective study. Aliment Pharmacol Ther. 2017 Dec;46(11-12):1077–84.

34 Greener T, Bolland K, Steinhart AH, Silverman JR, Scott BB, Flint L, et al. Combination therapy with infliximab in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14+ macrophages. Gastroenterology. 2011 Dec;141(6):2026–38.

35 Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr;106(4):644–59; quiz 660.

36 Billoud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review. Am J Gastroenterol. 2011 Apr;106(4):674–84.

37 Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol. 2009 Mar;104(3):760–7.

38 Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Korbluth A, Rachmilewitz D, et al.; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010 Apr;362(15):1383–95.

39 Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Korbluth A, Rachmilewitz D, et al.; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010 Apr;362(15):1383–95.
54 Meyer A, Rudant J, Drouin J, Weill A, Car-

50 Danese S, Gomollon F; Governing Board and

48 Kopylov U, Mantzaris GJ, Katsanos KH, Re-

43x468 58 Strik AS, van de Vrie W, Bloemsaat-Minekus

43x326 nator infliximab (NOR-SWITCH): a 52-week,  

43x278 77. Weaver KN, Gregory M, Syl G,Hoversten P,  

43x221 81 Sands BE, Chen J, Feagan BG, Penney M, Rees  

43x192 23, in Patients with Moderate to Severe  

43x183 and genetic basis of inflammatory bowel dis-

43x107 Gastroenterology. 2018 May;  154(6):S-

43x116 Severe Ulcerative Colitis in a Phase 2 Study.  

43x211 WA, Danese S, et al. Efficacy and Safety of  

43x202 MEDI2070, an Antibody against Interleukin  

43x249 Crohn’s disease: an open-label extension  

43x230 study. Lancet Gastroenterol Hepatol. 2018  

43x240 study. Lancet. 2017 Apr;389(10086):2034–16.  

43x677 Combination and Risk of Lymphoma in Pa-

43x620 Salzberg BA, Diamond RH, Price S, et al.  

43x667 Necrosis Factor Antagonists Alone or in  

43x686 Patient Survival in the TREAT TM registry.  

43x648 Induction and Maintenance Therapy for  

43x677 Patient Survival in the TREAT TM registry.  

43x601 Use of Thiopurines or Tumor  

43x582 77. Battat R, Kopylov U, Bessissow T, Bitton A,  

43x515 Salzberg BA, Safdi M, Popp JW Jr, et al.  

43x525 EC sergeant D, Zou B, Johanns J, et al. Long-term  

43x506 Bowel Dis. 2019;4:79–96

43x97 1360–S-1361.

43x544 Ustekinumab for Inducing Endoscopic Heal-

43x534 Ustekinumab for Inducing Endoscopic Heal-

43x553 Opportunistic Infections Associated with Treat-

43x563 Carbonnel F, Dray-Spira R. Risk of Serious and  

43x582 Terol. 2012 Sep;  107(9):  1409–22.

43x549 Ustekinumab during 28 weeks. Gastroenterology.  

43x591 up in the TREAT TM registry. Am J Gastroen-

43x572 JAMA. 2017 Nov;  318(17):  1679–86.

43x563 Terol. 2012 Sep;  107(9):  1409–22.

43x582 Terol. 2012 Sep;  107(9):  1409–22.

43x572 JAMA. 2017 Nov;  318(17):  1679–86.

43x563 Terol. 2012 Sep;  107(9):  1409–22.

43x582 Terol. 2012 Sep;  107(9):  1409–22.

43x572 JAMA. 2017 Nov;  318(17):  1679–86.

43x563 Terol. 2012 Sep;  107(9):  1409–22.

43x582 Terol. 2012 Sep;  107(9):  1409–22.

43x572 JAMA. 2017 Nov;  318(17):  1679–86.

43x563 Terol. 2012 Sep;  107(9):  1409–22.

43x582 Terol. 2012 Sep;  107(9):  1409–22.
From Pathogenesis to Therapy in IBD

83 Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003 Jan;52(1):65–70.

84 Frieder J, Kivelevitch D, Menter A. Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. Ther Adv Chronic Dis. 2018 Jan;9(1):5–21.

85 Pavelka K, Kivitz A, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study. MEASURE 3. Arthritis Res Ther. 2017 Dec;19(1):285.

86 Hueber W, Sands BE, Lewitzky S, Van-Demulderboecke M, Reinsich W, Higgins PD, et al.; Secukinumab in Crohn’s Disease Study Group. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012 Dec;61(12):1693–700.

87 Fobelo Lozano MJ, Serrano Giménez R, Castro Fernández M. Emergence of Inflammatory Bowel Disease during Treatment with Secukinumab. J Crohns Colitis. 2018. [Epub ahead of print].

88 Whibley N, Gaffen SL. Gut-Busters: IL-17 Ain’t Afraid of No IL-23. Immunity. 2015 Oct;43(4):620–2.

89 Lee JS, Tato CM, Joyce-Shaikh B, Gullen MF, Cayatte C, Chen Y, et al. Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability. Immunity. 2015 Oct;43(4):727–38.

90 Maxwell JR, Zhang Y, Brown WA, Smith CL, Byrne FR, Fiorino M, et al. Differential Roles for Interleukin-23 and Interleukin-17 in Inflammatory Immunoregulation. Immunity. 2015 Oct;43(4):739–50.

91 Soendergaard C, Seidelin JB, Steenholdt C, Maxwell JR, Zhang Y, Brown WA, et al. Randomised, double-blind, placebo-controlled trial. Gut. 2012 Dec;61(12):1693–700.

92 Ito H, Takazoe M, Fukuda Y, Hibi T, Kusu-gami K, Andoh A, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterology. 2004 Apr;126(4):989–96.

93 Danese S, Vermeire S, Hellström P, Panaccione R, Rogler G, Fraser G, et al. Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II). Gut. 2019 Jan;68(1):40–8.

94 Xie F, Yun H, Bernatsky S, Curtis JR. Brief Report: Risk of Gastrointestinal Perforation among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biological Therapies. Arthritis Rheumatol. 2016 Nov;68(11):2612–7.

95 Gout T, Östör AJ, Nisar MK. Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. Clin Rheumatol. 2011 Nov;30(11):1471–4.

96 West NR, Hegazy AN, Owens BM, Bullers SJ, Linggi B, Buonocore S, et al.; Oxford IBD Cohort Investigators. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 2017 May;23(5):579–89.

97 Gerlach K, Hwang Y, Nikolaev A, Atreye R, Dornhoff H, Steiner S, et al. TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nat Immunol. 2014 Jul;15(7):676–86.

98 Gerlach K, McKenzie AN, Neurath MF, Weigmann B. IL-9 regulates intestinal barrier function in experimental T cell-mediated colitis. Tissue Barriers. 2015 Apr;3(1-2):e983777.

99 Raker VK, Becker C, Steinbrink K. The cAMP Pathway as Therapeutic Target in Autoimmune and Inflammatory Diseases. Front Immunol. 2016 Mar;7:123.

100 Serezani CH, Ballinger MN, Aronoff DM, Byrne FR, et al. Differential Roles for Interleukin-23 and Interleukin-17 in Inflammatory Immunoregulation. Immunity. 2015 Oct;46(3):345–54.

101 Weigmann B, Neurath M, Popv Y, Horan G, Schafer P. P-257 Apremilast Prevents Intestinal Inflammation in Colitis Models via Influencing Epithelial Barrier. Inflamm Bowel Dis. 2017 Feb;23(suppl_1):S84.

102 Danese S, Neurath M, Kopon A, Zakko S, Simmons T, Fogel R, et al. cAMP regulates IL-10 production by normal human T lymphocytes at multiple levels: a potential role for MEF2. Mol Immunol. 2009 Jan;46(3):345–54.

103 O’Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013 Jan;368(2):161–70.

104 Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol. 2003 Nov;3(11):900–11.

105 Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014 Jun;57(12):5023–38.

106 Stewart KD, Johnston JA, Matza LS, Curtis SE, Havel HA, Sweetnea SA, et al. Preference for pharmaceutical formulation and treatment process attributes. Patient Prefer Adherence. 2016 Jul;10:1385–99.

107 Boland BS, Vermeire S, Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn’s Disease. Gastroenterol Clin North Am. 2017 Sep;46(3):627–44.

108 De Vries LC, Wildenberg ME, De Jonge WJ, D’Haens GR. The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease. J Crohns Colitis. 2017 Jul;11(7):885–93.

109 Neurath MF. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017 May;14(5):269–78.

110 Sandborn WJ, Gersh N, Panes J, Vranic I, Su C, Rousell S, et al.; Study A3921063 Investigators. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012 Aug;367(6):616–24.

111 Sandborn WJ, Su C, Panes J. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017 Aug;377(5):496–7.

112 Colonosc JF, Herpes Zoster in Patients Receiving JAK Inhibitors for Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention. Inflamm Bowel Dis. 2018 Sep;24(10):2173–82.

113 Charles-Schoeman C, Gonzalez-Gay MA, Kaplan I, Boy M, Geier J, Luo Z, et al. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. Semin Arthritis Rheum. 2016 Aug;46(1):71–80.

114 Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017 Jul;76(7):1253–62.

115 FDA. Safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz, Xeljanz XR) in rheumatoid arthritis patients; FDA to investigate [Internet]. Available from: https://www.fda.gov/Drugs/Safety aucm31871.htm.

116 Maneiro JR, Souto A, Gomez-Reino JJ. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: systematic review, meta-analysis, and network meta-analysis. Semin Arthritis Rheum. 2017 Oct;47(2):149–56.

117 Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 2018 Jan;47(2):162–75.

118 Hansema P, Panacccione R, Danese S, Cheifetz A, Reinsich W, Higgins PDR, et al. Tofacitinib Induction Therapy Reduces Symptoms within 3 Days for Patients with Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019 Jan;17(1):139–47.

119 Panès J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D’Haens G, et al. Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017 Jun;66(6):1049–59.
122 Vermeire S, Schreiber S, Petryka R, Kuehbach T, Hebuterne X, Robin X, et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017 Jan;389(10066):266–75.

123 Sandborn WJ, Feagan BG, Panes J, D’Haens GR, Colombel JF, Zhou Q, et al. Safety and Efficacy of ABT-494 (Upadacitinib), an Oral JAK1 Inhibitor, as Induction Therapy in Patients with Crohn’s Disease: Results from Celest. Gastroenterology. 2017 Apr;152(S5):S1308–S1309.

124 Sands BE, Sandborn WJ, Feagan BG, Lichtenstein GR, Zhang H, Strauss R, et al. Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-Severe Ulcerative Colitis: Results from a Randomized, Phase 2 Study. J Crohns Colitis. 2018;12(10):1158–69.

125 Xie JH, Gillooly K, Zhang Y, Yang X, Zupa-Fernandez A, Cheng L, et al. 349 – BMS-986165 is a Highly Potent and Selective Allosteric Inhibitor of TYK2, Blocks IL-12, IL-23 and Type I Interferon Signaling and Provides for Robust Efficacy in Preclinical Models of Inflammatory Bowel Disease. Gastroenterology. 2018;154(6):S1357.

126 Bristol-Myers Squibb. An Investigational Study of Experimental Medication BMS-986165 in Patients With Moderate to Severe Crohn’s Disease [Internet]. Available from: https://ClinicalTrials.gov/show/NCT03599622.

127 Beattie D, TsuRuda P, Shen F, Brassil P, Langrish C, Janc J, et al. P069 TD-1473, a novel, potent, and orally administered, GI-targeted, pan-JAK inhibitor (JAK) inhibitor. J Crohns Colitis. 2016;10:S123.

128 Sandborn WJ, Bhandari R, Leighton J, Gaughrish C, Janc J, et al. P069 TD-1473 demonstrates safety and efficacy of filgotinib in Crohn’s disease. Cochrane Database Syst Rev. 2018 Aug;8:CD006097.

129 Sakuraba A, Keyashian K, Correia C, Melek R, Cohen RD, Hanauer SB, et al. Natalizumab in Crohn’s disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis. 2013 Mar;19(3):621–6. Juillerat P, Wasan SK, Fowler SA, Friedman S, Pabby VK, Coukas JA, et al. Efficacy and safety of natalizumab in Crohn’s disease patients treated at 6 Boston academic hospitals. Inflamm Bowel Dis. 2013 Oct;19(11):2457–63.

130 Avasarala J. The TOUCH program and natalizumab: fundamental flaw in patient protection. F1000 Res. 2015 Dec;4:1450.

131 Ghosh S. Biologic therapies: lessons from multiple sclerosis. Dig Dis. 2012(30):438–6.

132 Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al.; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug;369(8):699–710.

133 Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al.; GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013 Aug;369(8):711–21.

134 Feagan BG, Robin DT, Danese S, Vermeire S, Abhyankar S, Sankoh S, et al. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients with Ulcerative Colitis, regardless of Prior Exposure to Tumor Necrosis Factor Antibodies. Clin Gastroenterol Hepatol. 2017 Feb;15(2):229–39.e5.

135 Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Wy R, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014 Sep;147(3):618–27.e3.

136 Loftus EV Jr, Colombel JF, Feagan BG, Vermeire S, Sandborn WJ, Sands BE, et al. Long-term Efficacy of Vedolizumab for Ulcerative Colitis. J Crohns Colitis. 2017 Apr;11(4):400–11.

137 Vermeire S, Loftus EV Jr, Colombel JF, Feagan BG, Sandborn WJ, Sands BE, et al. Long-term Efficacy of Vedolizumab for Crohn’s Disease. J Crohns Colitis. 2017 Apr;11(4):412–24.

138 Chaparro M, Garre A, Ricart E, Iborra M, Mesonero F, Vera I, et al.; GETECCU study group. Short- and Long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. Aliment Pharmacol Ther. 2018 Oct;48(8):839–51.

139 Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D’Haens G, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2017 May;66(5):839–51.

140 Eriksson C, Marsal J, Bergemalm D, Vigen L, Bjork J, Eberhardson M, et al.; SWIBREG Vedolizumab Study Group. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Scand J Gastroenterol. 2017 Jun;52(6–7):722–9.

141 Dalai PS, Singh S, Jiang X, Peerani F, Narula N, Chaudrey K, et al. The Real-World Efficacy and Safety of Vedolizumab for Moderate-Severe Crohn’s Disease: Results from the US VICTORY Consortium. Am J Gastroenterol. 2016 Aug;111(8):1147–55.

142 Vermeire S, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, et al. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. Am J Gastroenterol. 2018 Sep;113(9):1345–54.

143 Amiot A, Grimaud JC, Peyrin-Biroulet L, Filippi J, Patrione B, Robin X, et al. Efficacy and Safety of Vedolizumab Induction Therapy for Patients with Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2016 Nov;14(11):1593–1601.e2.

144 Noman M, Ferrante M, Bischops R, De Hertogh G, Van den Broeck K, Rans K, et al. Vedolizumab Induces Long-term Mucosal Healing in Patients with Crohn’s Disease and Ulcerative Colitis. J Crohns Colitis. 2017 Sep;11(9):1085–93.

145 Vermeire S, Gils A, Accossato P, Lula S, Marron A. Immunogenicity of biologics in inflammatory bowel disease. Therap Adv Gastroenterol. 2018 Jan;11:1756283X17750355.

146 Peyrin-Biroulet L, Danese S, Argollo M, Pouillon I, Peppas S, Gonzalez-Lorenzo R, et al. Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients with Crohn’s Disease or Ulcerative Colitis: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2019 Apr;17(5):838–46.e2.
From Pathogenesis to Therapy in IBD

Shmidt E, Kochhar G, Hartke J, Chilukuri P, Resve J, Chaudrey K, et al. Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. *Inflamm Bowel Dis*. 2018 Oct;24(11):2461–7.

Pouillon L, Van Stappen J, Bossuyt P, Danse S, Peyrin-Biroulet L. Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis? *Best Pract Res Clin Gastroenterol*. 2018 Feb-Apr;32-33:17–25.

Bryant RV, Sandborn WJ, Travis SP. Introducing vedolizumab to clinical practice: who, when, and how? *J Crohns Colitis*. 2015 Apr;9(4):356–66.

Scott FI, Shah Y, Lasch K, Luo M, Lewis JD. Assessing the Optimal Position for Vedolizumab in the Treatment of Ulcerative Colitis: A Simulation Model. *Inflamm Bowel Dis*. 2018 Jan;24(2):286–95.

Derrir RJ, Samaan MA, Powell N, Irving PM. Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis. *Clin Exp Gastroenterol*. 2017 Mar;10:57–66.

Feagan BG, Schwartz D, Danese S, Rubin DT, Lissoos TW, Xu J, et al. Efficacy of Vedolizumab in Fistulising Crohn’s Disease: Exploratory Analyses of Data from GEMINI-2. *J Crohns Colitis*. 2018 Apr;12(5):621–6.

Takeda. Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn’s Disease [Internet]. Available from: https://ClinicalTrials.gov/show/NCT02630966.

Vermeire S, O’Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. *Lancet*. 2014 Jul;384(9940):309–18.

Sandborn WJ, Cyrille M, Berner Hansen M, Feagan BG, Loftus Jr EV, Vermeire S, et al. OP035 Efficacy and safety of abirateron (AMG 181/MEDI 7183) therapy for moderate to severe Crohn’s disease. *Gastroenterology*. 2017;152:SS598.

Sandborn WJ, Cyrille M, Berner Hansen M, Feagan BG, Loftus Jr EV, Rogler G, et al. Efficacy and safety of abirateron in subjects with moderate to severe ulcerative colitis: results of a phase 2b, randomized, double-blind, multiple-dose, placebo controlled study. *Gastroenterology*. 2017 Apr;152(5):S598.

Vermeire S, Sandborn WJ, Danese S, Hebuterne RX, Salberg BA, Kloepocka M, et al. Anti-MaDCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. *Lancet*. 2017 Jul;390(10090):135–44.

Sandborn WJ, Lee SD, Tarabar D, Louis E, Kloepocka M, Klaus J, et al. Phase II evaluation of anti-MaDCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study. *Gut*. 2018 Oct;67(10):1824–35.

Sugita T, Kagayama S, Andou M, Miyazawa T, Ejima C, Nakayama A, et al. Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice. *J Crohns Colitis*. 2013 Dec;7(11):e533–42.

Yoshimura N, Watanabe M, Motomyo S, Tomina K, Matsuoka K, Iwakiri R, et al. Safety and Efficacy of AJM300, an Oral Antagonist of apha4 Integrin, in Induction Therapy for Patients with Active Ulcerative Colitis. *Gastroenterology*. 2015;149:1775–83.e2.

Takaoze MW, Kawabata T, et al. Oral alpha-4 integrin inhibitor (AJM300) in patients with active Crohn’s Disease – a randomised, double-blind, placebo-controlled trial. *Gastroenterology*. 2009;136(5):A181.

Proponent Therapeutics. Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Crohn’s Colitis [Internet]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT02895100.

Peyrin-Biroulet L, Christopher R, Behan D, Lassen C. Modulation of sphingosine-1-phosphate in inflammatory bowel disease. *Autoimmun Rev*. 2017 May;16(5):495–503.

Nelsen OH, Li Y, Johansson-Lindborn B, Coskun M. Sphingosine-1-Phosphate Signaling in Inflammatory Bowel Disease. *Trends Mol Med*. 2017 Apr;23(4):362–74.

Sandborn WJ, Feagan BG, Wolf DC, D’Haens G, Vermeire S, Hanauer SB, et al.; TOUCHSTONE Study Group. Azainodim Induction and Maintenance Treatment for Ulcerative Colitis. *N Engl J Med*. 2016 May;374(18):1754–62.

Arvin AM, Wolinsky JS, Kappos L, Morris DT, Lissoos TW, Xu J, et al. Etralsimod as induction therapy for ulcerative colitis: a phase 2b, randomised, double-blind, placebo-controlled study. *Trends Mol Med*. 2017 Apr;23(4):362–74.

Stremmel W, Merle U, Zahn A, Autschbach F, Hinze U, Ehehalt R. Retarded release phosphatidylycholine benefits patients with chronic active ulcerative colitis. *Gut*. 2005 Jul;54(7):966–71.

Stremmel W, Braun A, Hanemann A, Ehehalt R, Autschbach F, Karner M. Delayed release phosphatidylycholine in chronic-ac
tive ulcerative colitis: a randomized, double-blinded, dose finding study. *J Clin Gastroenterol*. 2010 May-Jun;44(5):e101–7.

Stremmel W, Ehehalt R, Autschbach F, Karner M. Phosphatidylycholine for steroid-refractory chronic ulcerative colitis: a randomized trial. *Ann Intern Med*. 2007 Nov;147(9):603–10.

Karner M, Kocjan A, Stein J, Schreiber S, von Boyen G, Uebel P, et al. First multicenter study of modified release phosphatidylycholine “LT-02” in ulcerative colitis: a randomized, place
cbo-controlled trial in mesalazine-refractory courses. *Am J Gastroenterol*. 2014 Jul;109(7):1041–51.

Dr. Falk Pharma GmbH. Phosphatidylycholine (LT-02) for Induction of Remission in Ulcerative Colitis [PROTECT-1]. [Internet]. Available from: https://ClinicalTrials.gov/ show/NCT02142725.

Stremmel W, Staffer S, Gehrkse S. The Detergent Effect of Mesalazine Interferes with Phosphatidylycholine Binding to Mucin 2. *Inflamm Intest Dis*. 2019 Feb;3(3):107–15.

Pascal V, Pozuelo M, Borruel N, Casellas F, Campos D, Santiago A, et al. A microbial signature for Crohn’s disease. *Gut*. 2017 May;66(5):813–22.

Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, et al. Low counts of Faecalibacterium prausnitzii in collitis microbiota. *Inflamm Bowel Dis*. 2009 Aug;15(8):1183–9.
192 Loh G, Blaut M. Role of commensal gut bacteria in inflammatory bowel diseases. *Gut Microbes*. 2012 Nov-Dec;3(6):544–55.

193 Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. *Gastroenterology*. 2014 May;146(5):1489–99.

194 David LA, Maurice CF, Carmody RN, Goon- tenberg DB, Button JE, Wolfe BE, et al. Diet rapidly and reproducibly alters the human gut microbiome. *Nature*. 2014 Jan;505 (7484):559–63.

195 Sigall-Boneh R, Levine A, Lomer M, Ramasundara M, Leach ST, Lemberg DA, et al. Effect of probiotics on in the treatment of experimental colitis in Crohn’s disease, and pouchitis: meta-analysis of randomised controlled trials. *Inflamm Bowel Dis*. 2014 Jan;20(1):21–35.

196 Schultz M. Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. *Inflamm Bowel Dis*. 2008 Jul;14(7):1012–8.

197 Orel R, Kamhi Trop T. Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease. *World J Gastroenterol*. 2014 Sep;20(33):11505–24.

198 Wehkamp J, Harder J, Wehkamp K, Wehkamp-von Meissner B, Schlee M, Enders C, et al. NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. *Infect Immun*. 2004 Oct;72(10):5750–8.

199 Shi J. Defensins and Paneth cells in inflammatory bowel disease. *Inflamm Bowel Dis*. 2007 Oct;13(10):1284–92.

200 Ramasundara M, Leach ST, Lemberg DA, Day AS. Defensins and inflammation: the role of defensins in inflammatory bowel disease. *J Gastroenterol Hepatol*. 2009 Feb;24(2):202–8.

201 Wehkamp J, Stange EF. Is there a role for defensins in IBD? *Inflamm Bowel Dis*. 2008 Oct;14 Suppl 2:585–7.

202 Koeninger L, Armbruster NS, Hu Z, Jensen B, Stange E, Nordkild P, et al. 129 – Oral delivery of Human β-defensin 2 is reversibly increasing microbiome diversity and is effective in the treatment of experimental colitis. *Gastroenterology*. 2018;154(6):S-34–S-35.

203 Khan KJ, Ullman TA, Ford AC, Abreu MT, Abdair A, Marshall JK, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. *Am J Gastroenterol*. 2011 Apr;106(4):661–73.

204 Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, et al. Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. *Gastroenterology*. 1995 Jun;108(6):1617–21.

205 Shiri E, Achkar JP, Lashner BA, Ormsby AH, Remzi FH, Brzezinski A, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. *Inflamm Bowel Dis*. 2001 Nov;7(4):301–5.

206 Sigall-Boneh R, Levine A, Lomer M, Ramasundara M, Leach ST, Lemberg DA, et al. Diet rapidly and reproducibly alters the human gut microbiome. *Nature*. 2014 Jan;505 (7484):559–63.

207 Smits LP, Bouter KE, de Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. *Gastroenterology*. 2013 Nov;145(5):946–53.

208 van Nuland ES, Cysne MA, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. *N Engl J Med*. 2013 Jan;368(5):407–15.

209 Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. *J Crohns Colitis*. 2014 Dec;8(12):1180–90.

210 Shi J, Zuo ZX, Mao AP. Effect of probiotics on in the treatment of experimental colitis in Crohn’s disease, and pouchitis: meta-analysis of randomised controlled trials. *Inflamm Bowel Dis*. 2014 Jan;20(1):21–35.

211 Rossen NG, Fuentes S, van der Spek MJ, Tijssen JG, Hartman JH, Duflou A, et al. Findings from a Randomized Controlled Trial of Fecal Transplantation for Patients with Ulcerative Colitis. *Gastroenterology*. 2015 Jul;149(1):110–8.e4.

212 Paramsothy S, Paramsothy R, Rubin DT, Kamm MA, Kaakoush NO, Mitchell HM, et al. Fecal Microbiota Transplantation for Inflammatory Bowel Disease and Meta-analysis. *J Crohns Colitis*. 2017 Oct;11(10):1180–99.

213 Moayedi P. Update on Fecal Microbiota Transplantation for Crohn’s Disease. *J Crohns Colitis*. 2017 Oct;11(10):1180–99.

214 Snowdon JA, Brierley CK, Castilla-Llorente C, Labopin AH, Remzi FH, Brzezinski A, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. *Inflamm Bowel Dis*. 2001 Nov;7(4):301–5.

215 Snowdon JA, Brierley CK, Castilla-Llorente C, Labopin AH, Remzi FH, Brzezinski A, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. *Inflamm Bowel Dis*. 2001 Nov;7(4):301–5.

216 Garcia-Olmo D, Herreros D, Pascual JA, Del-Valle E, Zorrilla J, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. *Dis Colon Rectum*. 2009 Jan;52(1):79–86.

217 Molendijk I, Bonsing BA, Roelofs H, Peeters KC, Wasser MN, Djikstra G, et al. Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells Promote Healing of Refractory Perianal Fistulas in Patients with Crohn’s Disease. *Gastroenterology*. 2015 Oct;149(4):918–27.e6.

218 Xie M, Qin H, Luo Q, He X, He X, Lan P, et al. Comparison of Adipose-Derived and Bone Marrow Mesenchymal Stromal Cells in a Murine Model of Crohn’s Disease. *Dig Dis Sci*. 2017 Jan;62(1):115–23.

219 de la Portilla F, Alba F, Garcia–Olmo D, Herreras JM, Gonzalez FX, Galindo A. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn’s disease: results from a multicenter phase I/IIa clinical trial. *Int J Colorectal Dis*. 2013 Mar;28(3):313–23.

220 Bañez J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, et al.; ADMIRE CD Study Group Collaborators. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial. *Lancet*. 2016 Sep;388(10051):1281–90.

221 Bañez J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, et al.; ADMIRE CD Study Group Collaborators. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial. *Lancet*. 2016 Sep;388(10051):1281–90.

222 Panes J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, et al.; ADMIRE CD Study Group Collaborators. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial. *Lancet*. 2016 Sep;388(10051):1281–90.